An ambulance or medical transport company typically sells for 3.0x–6.0x Seller's Discretionary Earnings (SDE), or 0.5x–1.0x annual revenue, with 911-contracted operations commanding the premium end and non-emergency-only companies sitting at the lower end. The U.S. ambulance and medical transport industry generates approximately $30 billion in annual revenue across roughly 15,000 licensed ambulance services, including municipal departments, hospital-based services, and private companies. Private ambulance companies represent the most active M&A segment, with PE-backed EMS platforms, hospital systems, and regional operators all competing for quality operations with strong contract portfolios.

Seller's Discretionary Earnings — the owner's total economic benefit calculated by adding back salary, benefits, depreciation, and non-recurring costs to net income — is the standard valuation method for medical transport companies under $1M in annual earnings. In ambulance companies, SDE calculation requires careful treatment of fleet depreciation, which represents a real and significant recurring capital cost. Buyers compare depreciation add-backs against actual fleet condition and replacement timelines. Common add-backs include the owner's salary, health insurance, vehicle expenses, and personal costs. Companies at the lower end of the 3.0x SDE range typically operate non-emergency wheelchair and BLS transport without 911 contracts, have aging fleets, and depend on the owner for dispatch and operations management. Companies at 6.0x hold multiple 911 contracts, offer ALS and specialty transport, operate modern fleets, and have professional management handling daily operations.

Revenue multiples for medical transport companies fall between 0.5x and 1.0x, with the range reflecting dramatic differences in revenue quality between contracted 911 service and non-emergency transport. Revenue from 911 contracts is valued at the premium end because it is contractually guaranteed, geographically protected, and transfers with the business. Non-emergency revenue — wheelchair transport, inter-facility BLS, medical appointment transport — must be continuously marketed and is more vulnerable to competition and rate pressure. Revenue multiples are most useful when separated by service type: 911 revenue at 0.8x–1.0x and non-emergency revenue at 0.4x–0.6x.

For larger medical transport operations generating $1M or more in annual EBITDA — typically multi-base companies with 911 contracts, specialty transport capability, and regional geographic coverage — institutional buyers use EBITDA multiples in the 6x to 10x range. PE-backed EMS platforms are the most active institutional buyers, building regional and national ambulance networks through serial acquisition. Hospital systems acquire ambulance companies to control patient transport pathways. National ambulance companies acquire for geographic expansion and 911 contract portfolios.

The unique valuation factor in ambulance and medical transport is the municipal contract portfolio as a quasi-governmental franchise. A 911 contract is not merely a customer relationship — it is a government-granted right to provide emergency services in a defined territory, often with cost-recovery mechanisms, mutual aid obligations, and performance standards that create both revenue protection and competitive barriers. Winning a 911 contract typically requires years of relationship building, RFP competition, investment in community presence, and demonstrated response time performance. Once won, 911 contracts renew at high rates — municipalities rarely change ambulance providers absent serious performance failures — creating long-term revenue visibility that few other business types can match. This franchise-like quality is what drives premium valuations for 911-contracted ambulance companies. The contract portfolio essentially converts what would be a competitive, marketing-dependent business into a territory-protected operation with guaranteed call volume. Buyers model 911 contract value separately from non-emergency revenue and typically assign it a premium multiple reflecting the revenue protection and competitive barrier it provides. For owners considering a sale, winning additional 911 contracts or expanding existing contract territories is the highest-impact value creation strategy — each contract added can increase total business value by $200K–$500K or more depending on territory size and call volume.

The ambulance and medical transport M&A market is driven by consolidation economics — larger operators achieve better reimbursement rates, staffing efficiency, and equipment purchasing power. PE-backed platforms continue to acquire aggressively, building regional density. Hospital systems pursue transport integration. National companies expand geographically through acquisition. For companies with strong 911 contract portfolios, modern fleets, and efficient billing operations, the market offers competitive multiples. Non-emergency-only operators should focus on building contract relationships and fleet condition before pursuing a sale.

Use our free calculator above to get your instant estimate, then track your value monthly with YourExitValue.